UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
____________________________________________________________
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of 1934
___________________________________________________________________
Date
of
Report (Date of earliest event reported): April 21, 2008
Transdel
Pharmaceuticals, Inc.
(Exact
Name of Registrant as Specified in Charter)
|
Delaware
|
000-52998
|
45-0567010
|
||
|
(State
or other jurisdiction
of
incorporation)
|
(Commission
File Number)
|
(IRS
Employer
Identification
No.)
|
|
4225
Executive Square, Suite 460
La
Jolla, CA
|
92037
|
|
|
(Address
of principal executive offices)
|
(Zip
Code)
|
Registrant’s
telephone number, including area code: (858) 457-5300
|
n/a
|
|
(Former
name or former address, if changed since last
report)
|
Check
the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions:
o
Written communications
pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o
Soliciting material pursuant to Rule
14a-12 under the Exchange Act (17 DFR 240.14a-12)
o
Pre-commencement communications pursuant
to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o
Pre-commencement communications pursuant
to Rule 13e-4 (c) under the Exchange Act (17 CFR 240.13e-4(c))
Item
5.02. Departure
of Directors or Certain Officers; Election of Directors; Appointment of Certain
Officers; Compensatory Arrangements of Certain Officers.
Effective
April 21, 2008, our board of directors appointed Dr. Paul Finnegan as our Chief
Medical Officer and Chief Operating Officer. Dr. Finnegan served as President
and Chief Executive Officer of Cecoura Therapeutics, Inc. from October 2007
to March 2008. From April 2001 to September 2007, Dr. Finnegan held various
positions at Alexion Pharmaceuticals, Inc. Specifically, from 2006 to 2007,
Dr.
Finnegan served as Vice President, Global Strategic Marketing and Development
and as a member of the Management Committee. From 2002 to 2006, Dr. Finnegan
served as Vice President of Commercial Operations and Development at Alexion
Pharmaceuticals, Inc. From 1998 to 2000, Dr. Finnegan was Senior Director,
Global Medical Marketing at Pharmacia Corporation, formerly G.D.
Searle, and from 1993 to 1997 he served as Director and Partner of Toronto
East Radiology Associates, LLC. Dr. Finnegan received his MD and
CM degree from McGill University and an MBA in Finance/Strategy from the
University of Chicago, Graduate School of Business.
Item
8.01 Other
Events.
On
April
24, 2008, we issued a press release announcing that we appointed Dr. Paul
Finnegan as Chief Medical Officer and Chief Operating Officer.
Item
9.01 Financial
Statements and Exhibits.
(d)
Exhibits
|
Exhibit
No.
|
Description
|
|
99.1
|
Press
Release, dated April 24, 2008.
|
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the Registrant
has
duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
| TRANSDEL PHARMACEUTICALS, INC. | ||
| |
|
|
| Date: April 24, 2008 | By: | /s/ John T. Lomoro |
|
John T. Lomoro |
||
| Title: Chief Financial Officer | ||
EXHIBIT
INDEX
|
Exhibit
No.
|
Description
|
|
99.1
|
Press
Release, dated April 24, 2008.
|
Contact:
John
Lomoro
Chief
Financial Officer
Transdel
Pharmaceuticals, Inc.
858-457-5300
Transdel
Pharmaceuticals Appoints Chief Medical Officer and Chief Operating
Officer
LA
JOLLA,
Calif., April 24 /PRNewswire-FirstCall/ -- Transdel Pharmaceuticals, Inc. (OTC
Bulletin Board:
TDLP
-
News),
a
specialty pharmaceutical company focused on the development and
commercialization of non-invasive topically administered medications, today
announced the appointment of Dr. Paul Finnegan to the position of Chief Medical
Officer and Chief Operating Officer. In his new role, Dr. Finnegan will oversee
the Phase 3 clinical program for Transdel's lead product, Ketotransdel(TM),
a
novel topical cream based non-steroidal anti-inflammatory drug ("NSAID") for
the
treatment of acute pain. In addition, Dr. Finnegan will manage the development
and expansion of Transdel's clinical pipeline, leveraging the Company's
proprietary Transdel(TM) technology to develop enhanced generic and novel
products in a broad range of indications and therapeutic areas.
Dr.
Finnegan brings to the Company over a decade of experience in the development
and commercialization of multiple drugs through leadership roles in both public
and private biotechnology/pharmaceutical companies. His specific pain and
anti-inflammatory therapeutic experience includes Celebrex® (celecoxib), Bextra®
(valdecoxib), Dynastat® (paracoxib), and Arthrotec® (diclofenac sodium /
misoprostol) while at Pharmacia/G.D. Searle & Co. Dr. Finnegan joins the
Company from Cecoura Therapeutics, Inc., a privately held biotechnology firm,
where he served as President and Chief Executive Officer from October 2007
to
March 2008.
Dr.
Juliet Singh, President and Chief Executive Officer of Transdel Pharmaceuticals,
commented, "We are pleased to welcome Dr. Finnegan to our senior management
team. His extensive biotechnology and pharmaceutical industry experience,
particularly his focus on the areas of pain and inflammation, is directly
relevant to our ongoing clinical development programs. He will not only add
great value to the Phase 3 clinical program for Ketotransdel but also brings
an
excellent commercial background, which will be an asset as we advance
Ketotransdel to commercialization. Lastly, Dr. Finnegan's knowledge base and
capabilities will be integral to supporting our goal of expanding our pipeline
with innovative topically based products."
At
Cecoura, Dr. Finnegan was involved in clinical and drug development, where
he
led and completed an IND submission and was involved in licensing activities.
Dr. Finnegan held various positions at Alexion Pharmaceuticals, Inc. from April
2001 through September 2007. Specifically, from 2006 to 2007, he served as
Vice
President, Global Strategic Marketing and Development and as a member of the
Management Committee. In this role, he was directly responsible for building
Alexion's subsidiaries in country markets outside of the U.S. and Europe. From
2002 to 2006, Dr. Finnegan served as Alexion's Vice President of Commercial
Operations and Development. During this period, Dr. Finnegan was one of the
founders of the Soliris(TM) (eculizumab) PNH clinical development and
commercialization programs (US
and
EU approvals and launches in 2007), intimately involved in three cardiovascular
Phase III clinical registration trials (PRIMO-CABG1, PRIMO-CABG2, APEX-AMI),
member of the Alexion-Procter
and Gamble Pharmaceuticals Alliance Senior Management Team, and played an
instrumental role in building Alexion's European presence. He joined Alexion
as
Executive Director of Commercial Operations.
From
1998
to 2000, Dr. Finnegan was Senior Director, Global Medical Marketing at Pharmacia
Corporation, formerly G.D. Searle. While at Pharmacia/G.D. Searle, Dr. Finnegan
served as the medical affairs lead for all therapeutic areas and products
(pain/anti-inflammatory, cardiovascular, women's health and oncology franchises)
for businesses in Japan, Asia-Pacific, Latin America and Canada, and played
a
key role for the launch of the blockbuster Celebrex® / Celebra®, the first COX-2
inhibitor indicated for pain, osteoarthritis, and rheumatoid arthritis, in
the
regions.
From
1993
to 1997, Dr. Finnegan was Director and Partner of Toronto East Radiology
Associates, LLC, and was the co-leader of Vascular and Interventional Radiology
at Toronto East General & Orthopedic Hospital, an affiliated teaching
hospital of the University of Toronto. Dr. Finnegan earned his MBA with Honors,
in Finance and Strategy, from the University of Chicago, Graduate School of
Business. He also holds the degrees of MD, CM from McGill University, Faculty
of
Medicine, in Montreal and is a Fellow of the Royal College of Physicians, Canada
(FRCPC).
About
Transdel Pharmaceuticals, Inc.
Transdel
Pharmaceuticals, Inc. (OTC Bulletin Board: TDLP
-
News)
is a
specialty pharmaceutical company pursuing the development and commercialization
of non-invasive topically delivered medications. The Company's lead topical
drug, Ketotransdel, utilizes the Company's innovative patented Transdel(TM)
cream formulation technology to facilitate the passage of ketoprofen, an NSAID,
through the skin barrier to reach targeted underlying tissue where the drug
can
exert its prolonged localized anti- inflammatory and analgesic effect. The
Company is also investigating other drug candidates and treatments for
transdermal delivery using the patented Transdel platform technology for
products in pain management and other therapeutic areas. For more information,
please visit http://www.transdelpharma.com.
Safe
Harbor Statement
Statements
made in this release that are not historical in nature constitute
forward-looking statements within the meaning of the Safe Harbor Provisions
of
the Private Securities Litigation Reform Act of 1995. Forward-looking
statements can be identified by the use of words such as "expects," "plans,"
"will," "may," "anticipates," "believes," "should," "intends," "estimates,"
and
other words of similar meaning. These
statements are subject to risks and uncertainties that cannot be predicted
or
quantified and consequently, actual results may differ materially from those
expressed or implied by such forwardlooking statements. Such risks and
uncertainties include, without limitation, risks and uncertainties associated
with the uncertainty of future financial results, additional financing
requirements, development of new products, government approval processes, the
impact of competitive products or pricing, and technological changes. More
detailed information about the company and the risk factors that may affect
the
realization of forward-looking statements is set forth in the company's filings
with the Securities and Exchange Commission, including the company's Annual
Report on Form 10-KSB filed with the SEC on March 26, 2008. Such documents
may
be read free of charge on the SEC's web site at http://www.sec.gov.
All
forward-looking statements included in this release are made as of the date
of
this press
release, and the company assumes no obligation to update any such
forward-looking statements.